NC-KBI-BIOPHARM/ARGONAUT
16.1.2024 13:58:26 CET | Business Wire | Press release
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), and Argonaut Manufacturing Services, Inc. (Argonaut), a cGMP contract manufacturing organization (CMO) serving the biopharmaceutical and diagnostics industries, today announced a strategic alliance offering biopharmaceutical clients with end-to-end drug substance and drug product manufacturing solutions. The arrangement provides a seamless integration of drug substance and drug product manufacturing by combining KBI’s leading drug development and biologics manufacturing services with Argonaut’s expertise in sterile fill-finish. The alliance reinforces both companies’ commitment to support customers in bringing clinical and commercial therapies to patients quickly, safely, and efficiently.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240116635207/en/
Biopharmaceutical organizations are expected to benefit from this strategic collaboration through accelerated timelines and the scalable manufacturing capacities offered by both organizations.
“At KBI Biopharma, we have always been committed to delivering innovative solutions that accelerate the development and manufacturing of life-saving therapeutics. Our state-of-the-art facilities and world-class team have consistently pushed the boundaries of what is possible in biopharmaceutical development,” said J.D. Mowery, President and CEO of KBI Biopharma.
He continued, “Similarly, Argonaut has established itself as a trusted provider in the industry, known for its cutting-edge technologies and exceptional track record in drug product manufacturing. Their commitment to quality and efficiency aligns perfectly with our own values and vision. This collaboration represents a new era of collaboration and innovation in the biopharma industry.”
“We believe this strategic alliance resolves a key issue for biopharmaceutical organizations as it greatly improves the alignment and integration between two complex and critical aspects of drug development and manufacturing. Biopharmaceutical companies will benefit from an integrated solution that is faster, more flexible, and leverages the unique expertise of our two organizations,” said Wayne Woodard, Founder and CEO of Argonaut. “Argonaut’s fill-finish capabilities are scalable from first-in-human clinical material for rare diseases through commercial batches of approved products. With this collaboration, biopharmaceutical organizations can now seamlessly move from development to full-scale manufacturing, saving both time and capital expenditures.”
In January 2023, Argonaut announced a capital investment focused on the significant expansion of its Carlsbad, CA manufacturing facilities with increased capacity and scale, and this agreement with KBI furthers its commitment to continual growth.
About Argonaut Manufacturing Services, Inc.
Argonaut Manufacturing Services is an FDA-registered cGMP contract manufacturing organization (CMO) dedicated to providing custom manufacturing and supply chain solutions for biopharmaceutical and diagnostic companies. Aseptic drug fill/finish features state-of-the-art automated equipment for high-yield filling of sterile injectable drugs including biologics, peptides, small molecule, and vaccines. Diagnostic manufacturing includes proprietary lyophilization technology and a spectrum of kitting capabilities. Projects are supported with full analytical quality control services including warehousing and global shipping logistics. Serving innovators in the life science, molecular diagnostics, and biopharma industries, Argonaut provides a wide range of flexible solutions for diverse outsourcing needs.
More information available at www.argonautms.com.
About KBI Biopharma, Inc.
KBI Biopharma, Inc., a JSR Life Sciences company, together with its affiliates, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. As a global leader in mammalian cell line development, with best-in-class modular technology and highly specialized solutions, KBI enables the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. With each of its 500+ client partners, KBI works closely to personalize and rapidly accelerate drug development programs.
Global partners are utilizing KBI’s technologies to advance more than 160 drug candidates in preclinical and clinical development and the manufacture of ten commercial products. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates to the market. KBI serves its global partners with eight locations in Europe and the USA. More information is available at www.kbibiopharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240116635207/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MEX Exchange, Part of MultiBank Group Strengthens Leadership Team with Key Appointment3.8.2026 13:39:00 CEST | Press release
MEX Exchange, the institutional electronic trading platform of MultiBank Group, today announced the appointment of Vibhanshu Bahuguna as Senior Director, reinforcing the company's commitment to building a world-class leadership team as it expands its global institutional business and technology capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803009139/en/ MEX Exchange, the institutional electronic trading platform of MultiBank Group, today announced the appointment of Vibhanshu Bahuguna as Senior Director, reinforcing the company's commitment to building a world-class leadership team as it expands its global institutional business and technology capabilities. With more than 20 years of experience across sales, business development and electronic trading, Bahuguna joins MEX Exchange with extensive expertise in electronic trading solutions spanning EMS, OMS, OTC and ECN technologies across the foreign exchange
NIQ Returns to IFA 2026 to Lead Industry Conversations on Growth, Innovation, AI and Consumer Transformation3.8.2026 12:45:00 CEST | Press release
Exclusive insights, executive thought leadership and industry dialogue at the IFA Retail Leaders Summit and NIQ Business Breakfast As the Official Global Insights Partner of IFA Berlin 2026, NIQ (NYSE: NIQ) will continue to play a leading role shaping industry discussions , bringing together data, AI-driven intelligence, and human insight to illuminate the forces reshaping growth, innovation, and consumer behavior. Through executive keynotes, panel discussions, exclusive market intelligence, and strategic customer engagements (including participation in the IFA Retail Leaders Summit, the fourth NIQ Business Breakfast, and a dedicated SMB-focused event) NIQ will help translate rapid market change into actionable opportunity for the global technology ecosystem. Under this year’s IFA theme, “The Future Is Now,” NIQ will provide timely perspectives on the forces redefining consumer technology, home appliances, and retail—from AI-driven innovation and evolving shopper expectations to omnich
Prodalim Reports Q2 2026 Results, with Continued Accelerated Growth in its Specialty Ingredients & Solutions Business3.8.2026 12:03:00 CEST | Press release
SIS revenues (Specialty Ingredients & Solutions) grew 131% in Q2 to US$22 million.Group revenues for the quarter grew 16% to US$92.5 million.Adjusted EBITDA1 for the SIS grew by more than 3 times YoY to US$4.2 million, reflecting an adjusted EBITDA margin of 19.2%.The SIS business represented 24% of total revenues and 40% of adjusted EBITDA.Group’s adjusted net profit grew 4% to US$5.3 million.Cashflow from operating activities was strong, increasing to US$15.5 million. Tsahi Barak, Chairman of the Board and CEO of the Company, commented: "We are pleased to report another quarter of growth, highlighted by the increasing contribution of our Specialized Ingredients Solutions (SIS) business. We are clearly seeing the results of the transformation we have been leading over the past year, with revenue from our Specialized Ingredients Solutions business more than doubling compared to the same period last year. The business now contributes approximately 40% of the Group's adjusted EBITDA. We
Historic French Luxury Leather Goods House Moreau Paris Sold to Leading Manufacturer3.8.2026 11:00:00 CEST | Press release
ASTEREN announces that the Paris Commercial Court has approved the acquisition of Moreau Paris, one of France’s most prestigious luxury leather goods houses, by Cardinal Invest, owner of the French luxury manufacturer Groupe Lécuyer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803029803/en/ Paris flagship rue du Faubourg Saint-Honoré (source: Moreau Paris) The transaction concludes a competitive international sale process conducted under the supervision of the Paris Commercial Court and marks the beginning of a new chapter for one of the last independent historic Paris monogram houses. Led by judicial liquidator Pablo Castanon at ASTEREN, with Richard Morgan Advisory as financial advisor, the process launched in early June attracted substantial interest from trade and financial investors worldwide. The Court order signed on 29 July lays the foundations for renewed investment, international expansion and long-term indus
Kioxia to Showcase CXL™ Compatible Memory Expansion Module KIOXIA XL1 Series for AI Workloads3.8.2026 10:22:00 CEST | Press release
Kioxia Corporation, a world leader in memory solutions, today announced that it will exhibit the KIOXIA XL1 series, a Compute Express Link™ (CXL™) compatible memory expansion module, at the Kioxia booth at FMS: the Future of Memory and Storage, taking place August 4 - 6 in Santa Clara, CA. The product features KIOXIA XL-FLASH™, a low-latency and high-performance flash memory technology that enables flash memory, traditionally used for storage applications, to also be utilized as a memory expansion solution. In addition, it is being designed and developed to support the growing volume of memory-intensive AI applications. Evaluation samples are scheduled to be shipped to industry ecosystem collaborators in August 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803920975/en/ CXL™ Compatible Memory Expansion Module KIOXIA XL1 Series In recent years, the growing number of AI workloads has significantly increased memory de
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom